NCT06510491 - Epcoritamab in Previously Treated WM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2027

Conditions

Waldenstrom MacroglobulinemiaB-Cell Lymphoproliferative Disorder

Interventions

DRUG

Epcoritamab

Bispecific antibody, via subcutaneous (under the skin) injection per protocol.

Trial Locations (3)

RECRUITING

Beth Israel Deaconess Medical Center, Boston

NOT_YET_RECRUITING

Brigham and Women's Hospital, Boston

NOT_YET_RECRUITING

Dana-Farber Cancer Institute, Boston